Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01925001 |
|
Recruitment Status :
Withdrawn
(Sangart ceased operations)
First Posted : August 19, 2013
Last Update Posted : October 28, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Sickle Cell disease is caused by an inherited hemoglobin disorder. Healthy red blood cells are discoid and can deform and move through small blood vessels to carry oxygen to all parts of the body. In Sickle Cell disease, as red blood cells circulate and oxygen is released, the deoxygenated abnormal Hemoglobin S can begin to polymerize and cause red cells to become sticky and elongated. These "sickled" red cells are less flexible and will obstruct small blood vessels and prevent normal red cells from circulating freely, which limits oxygen delivery to tissues and organs. This is known as a "sickling crisis" or "vaso-occlusive crisis" and is the leading cause of hospitalization in patients with Sickle Cell disease.
Patients suffering from a sickle crisis experience severe pain and are at risk of stroke, heart attack or even death. Current therapy is limited to hydration and symptomatic pain relief. The administration of MP4CO as an adjunct treatment to standard therapy may alleviate pain associated with a sickling crisis and potentially reduce the severity and duration of a crisis. This may shorten the time in hospital and potentially improve the quality of life for patients with sickle cell anemia.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Anemia, Sickle Cell Sickle Cell Anemia Sickle Cell Disease Sickle Cell Disorders Hemoglobin SC Disease Sickle Cell Hemoglobin C Disease | Drug: MP4CO Drug: Sodium chloride solution | Phase 2 |
Sickle cell disease (SCD) is an autosomal recessive disorder of the β globin gene of the hemoglobin molecule. To date, no specific agent has been approved to treat a sickle cell crisis, to reduce the severity of a sickling crisis, or to shorten the duration of admission. Current therapy for a crisis is limited to hydration and symptomatic pain relief with opiates when pain is severe enough to cause admission to hospital. Administration of oxygen by inhalation alone has not proven effective. The carbon monoxide (CO) molecule binds to Hb S and, while attached, prevents and reverses polymerization of Hb S chains and the distortion of the red cell. CO at very low doses also acts as a cell-signaling molecule, and may reduce inflammation, decrease oxygen requirements, and prevent programmed cell death (apoptosis).
MP4CO is designed as an ischemic rescue therapy to deliver non-toxic levels of CO, to provide an immediate metabolic signal to cells to help reverse red cell sickling, and to reduce inflammation.
Previously published studies provide a foundation to postulate that MP4CO might have the appropriate properties for treatment or reversal of an acute sickling crisis. The initial release of CO from MP4CO is predicted to have a beneficial effect including immediate stabilization of Hb S to prevent further red cell polymerization and reverse existing sickling, dilation of capillaries to enhance tissue perfusion, and anti-inflammatory cell-signalling properties. The subsequent circulation of the MP4 molecule as an oxygen therapeutic (after converting to MP4OX following oxygenation in the lungs) will help to 1) preferentially oxygenate ischemic tissue, 2) reverse partially sickled red cells, and 3) improve perfusion and oxygenation of local tissues to potentially ameliorate the painful crisis caused by sickling of red cells. In addition, MP4CO has enhanced chemical stability, which enables storage at room temperature.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease |
| Study Start Date : | October 2013 |
| Estimated Primary Completion Date : | June 2015 |
| Estimated Study Completion Date : | October 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: MP4CO
Escalating doses of MP4CO, administered intravenously
|
Drug: MP4CO
43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
Other Names:
|
|
Active Comparator: Sodium chloride solution
Normal saline (0.9% Sodium Chloride Injection USP)administered intravenously
|
Drug: Sodium chloride solution
Normal saline solution (0.9% Sodium Chloride Injection USP)
Other Names:
|
- Duration of hospitalization for treatment of painful vaso-occlusive crisis (VOC) [ Time Frame: Up to 28 days ]Time from randomization to resolution of the vaso-occlusive crisis, assessed by evaluation of cessation of opioid analgesia, recovery of ambulation, and/or ready for hospital discharge.
- Pain levels [ Time Frame: Up to 7 days ]Proportion of subjects with a pre-defined reduction in pain levels assessed using a visual analogue scale (VAS)
- Readmission to emergency room (ER) [ Time Frame: Up to 28 days ]Proportion of subjects with at least one return visit to ER after hospital discharge
- Re-admission to hospital for treatment of VOC [ Time Frame: Up to 28 days ]Proportion of subjects re-admitted to hospital for VOC treatment within 7 days after discharge
- Acute Chest Syndrome (ACS) complications [ Time Frame: Up to 28 days ]Proportion of subjects with ACS complications
- Adverse events [ Time Frame: Up to 28 days ]Adverse events (AEs) assessed daily through 7 days, and Serious Adverse Events (SAEs) throughout Day 28 follow-up visit
- Urine biomarkers [ Time Frame: Up to 7 days ]Urinalysis, and biomarkers to evaluate renal function
- Ambulation [ Time Frame: Daily up to 7 days ]Ability to ambulate assessed by Chair Rise and 50-foot walk tests
- Pain diary [ Time Frame: Up to 1 year (on average) ]Electronic diary recording of daily pain levels using a visual analogue scale (VAS)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed Informed Consent (and assent as required for minors)
- Diagnosis of SCD (known HbSS or HbSß0)
- Sixteen years of age or older
- Prior history of at least one VOC requiring hospitalization within the last 24 months
Exclusion Criteria:
- ≥ 5 VOCs within the preceding 6 months requiring Emergency Room (ER) visits or hospital admissions
- History of overt stroke or cerebral vascular accident within the previous 12 months
- Remained in the hospital for ≥2 weeks (14 days) for VOC management within the previous 6 months
- Known pulmonary hypertension based on an estimated tricuspid regurgitant jet velocity (TRJV) >2.90 m/s or definitive diagnosis by prior right heart catheterization
- Baseline SaO2 level by pulse oximetry <92% on room air
- Systemic hypertension (baseline systolic pressure ≥ 160 mmHg or diastolic pressure ≥ 90 mmHg)
- History of myocardial infarction, myocardial ischemia, or angina
- On a chronic red blood cell transfusion therapy program (simple or exchange)
- Renal dysfunction presenting with a GFR<60 mL/min/1.73m
- Any diagnosis of a concurrent chronic debilitating disease that may affect the completion of the study or results of the study as determined by the investigator
- Currently enrolled in any other investigational treatment study
- Significant substance abuse.
- Known to have HIV, active hepatitis B, or C infection, or active tuberculosis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01925001
| Bahrain | |
| Salmaniya Medical Complex | |
| Manama, Bahrain | |
| Belgium | |
| University Hospital Brugmann | |
| Brussels, Belgium | |
| Brazil | |
| Rio de Janerio Instituto Estadual de Hematologie | |
| Rio de Janerio, Brazil | |
| France | |
| Hôpital Henri Mondor | |
| Créteil, France | |
| Georges Pompidou European University Hospital | |
| Paris, France | |
| Lebanon | |
| American Univ. of Beirut Medical Center | |
| Beirut, Lebanon | |
| Univ. Medical Center Rizk Hospital | |
| Beirut, Lebanon | |
| Netherlands | |
| Academic Medical Center | |
| Amsterdam, Netherlands | |
| Qatar | |
| Cornell Medical City | |
| Doha, Qatar | |
| Turkey | |
| Cukurova University Medical Facilty | |
| Adana, Turkey | |
| Mersin University Medical Faculty | |
| Mersin, Turkey | |
| United Kingdom | |
| Guys Hospital | |
| London, United Kingdom | |
| King's College Hospital | |
| London, United Kingdom | |
| Queen Mary Hospital | |
| London, United Kingdom | |
| Study Director: | Tania Small, MD | Sangart, Inc., San Diego, CA | |
| Principal Investigator: | Swee Lay Thein, MD | King's College Hospital NHS Trust |
| Responsible Party: | Sangart |
| ClinicalTrials.gov Identifier: | NCT01925001 |
| Other Study ID Numbers: |
SCD-206 |
| First Posted: | August 19, 2013 Key Record Dates |
| Last Update Posted: | October 28, 2013 |
| Last Verified: | October 2013 |
|
Sickle cell anemia Sickle cell disease Sickling crisis Vaso-occlusive crisis Carboxyhemoglobin |
Oxygen therapeutic Ischemic rescue therapy Hemoglobin solution Pegylated hemoglobin |
|
Anemia Anemia, Sickle Cell Hemoglobin SC Disease Hemoglobin C Disease Hematologic Diseases |
Anemia, Hemolytic, Congenital Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn Pharmaceutical Solutions |